Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
This overview identifies factors that influence which Dividend Etf Has Best Tax Treatment, including distribution type, fund turnover, and tax lots.
27,987 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
An AI-led forecast suggests ripple (xrp) price prediction could push XRP to $500 by 2035, renewing debates about the ...
Applied Optoelectronics leads a broad optics rally, jumping 24% as AI-driven data-center capex fuels demand for high-...
As negotiators in Beijing steer talks between the U.S. and China, investors are eyeing three names likely to move: NV...
A major fund trimmed its stake in a biotech ahead of a June FDA milestone. This article explains what that means for ...
Google's I/O showcased a sweeping pivot to AI, signaling major changes for everyday tools and consumer budgets as the...
Republic Services is tightening up near key moving averages, raising odds for a golden cross. This report surveys the...
XRP tests the $1.40 support as bulls fight for momentum. Here are the three signals shaping its path this week.
Eastwood Homes announced it will acquire Peachtree Building Group, signaling that scale is now a mandatory criterion ...
ECB board member Isabel Schnabel presses for a digital euro to counter stablecoin risks, signaling tighter regulation...
The White House has tapped a real-estate heir as acting director of national intelligence, a move that drew sharp que...
SpaceX is entering the IPO spotlight, but valuing a space, AI, and satellite powerhouse is unique. This guide breaks ...